Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00723775 | GSK706769/KALETRA Drug-drug Interaction Study | PHASE1 | COMPLETED | 17 | — | — | Jul 24, 2008 | Nov 8, 2008 | Jul 21, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Part 1 | OTHER | GSK706769 new vs. current formulation; GSK706769 alone vs. GSK706769 plus Kaletra |
| Part 2 | OTHER | GSK706769 alone for 10 days; GSK706769 + Kaletra for 14 days |
| Name | Type | Description |
|---|---|---|
| GSK706769 & KALETRA | DRUG | GSK706769 alone and GSK706769 + Kaletra |
Inclusion Criteria: * Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the populati...